This HTML5 document contains 157 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34373867
rdf:type
wikibase:Item
schema:description
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված 2013년 논문 наукова стаття, опублікована у вересні 2013 научни чланак научна статия мақолаи илмӣ artigo científico سائنسی مضمون 2013年论文 artigo científico (publicado na 2013) 2013年論文 научни чланак artykuł naukowy artikull shkencor 2013年论文 mokslinis straipsnis artículo científico publicado en 2013 wetenschappelijk artikel 2013 nî lūn-bûn articol științific 2013年論文 vědecký článek სამეცნიერო სტატია bilimsel makale scienca artikolo 2013年論文 επιστημονικό άρθρο 2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած 2013年の論文 article científic научная статья wissenschaftlicher Artikel 2013年论文 vitskapeleg artikkel مقالهٔ علمی article scientific artikulong pang-agham 2013年论文 article scientifique (publié 2013) naučni članak מאמר מדעי 2013年論文 artículu científicu espublizáu en 2013 vedecký článok tieteellinen artikkeli مقالة علمية 2013年论文 vitenskapelig artikkel bài báo khoa học artigo científico (publicado na 2013) articolo scientifico мақолаи илмӣ 2013年論文 tudományos cikk บทความทางวิทยาศาสตร์ teaduslik artikkel ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vetenskaplig artikel scientific article 2013年论文 videnskabelig artikel (udgivet 2013)
p:P577
wds:Q34373867-69C185AA-4CBF-4D03-A762-ADBA0B38B1CF
wdt:P577
2013-09-25T00:00:00Z
p:P2860
wds:Q34373867-F179BEA8-A845-4437-B048-09E282ACE450 wds:Q34373867-B00ADADB-A2EF-4547-9CD0-D9972910E3B2 wds:Q34373867-BE643327-8405-4413-B851-8EBBBE9870DC wds:Q34373867-CCB6B882-A691-40CD-8B9F-9EACFB22CD7D wds:Q34373867-A379A1CD-1154-45AC-971A-3847C9DFAE5A wds:Q34373867-A997F5A1-3BE7-4EAA-965E-8C5E899E724D wds:Q34373867-86EA7B28-7EA8-493E-B549-D58D8575A82C wds:Q34373867-8C7F893D-1FAA-4678-AAD9-CDBA71D3F325 wds:Q34373867-545325E2-94B2-494B-8B6F-8C88ADB762AD wds:Q34373867-64D9796A-F4D6-4053-A649-B356ACD06B67 wds:Q34373867-4A611AA3-B0F5-4190-B7D0-7302A6226327 wds:Q34373867-346D063F-85A7-4F77-9027-BAF5FB659E4C wds:Q34373867-3CA5A284-66FF-461A-B581-F2916E658F5F wds:Q34373867-42397647-3042-4ED6-A7D6-B153F63C973A wds:Q34373867-15F127D3-9BAB-45CD-917C-4C9CE1BE521A wds:Q34373867-219A3693-A964-4C4B-8D5E-A9D60044985C wds:Q34373867-0329762E-26D8-4943-A080-3FA1090C20B6 wds:Q34373867-145C4971-E267-4BF9-9DDC-D9861FFFD3D0
wdt:P2860
wd:Q39734035 wd:Q93569641 wd:Q37790212 wd:Q42111140 wd:Q36729925 wd:Q43092892 wd:Q42285688 wd:Q84501396 wd:Q37153512 wd:Q34296639 wd:Q44304694 wd:Q37208045 wd:Q38375842 wd:Q38021847 wd:Q58000796 wd:Q33559015 wd:Q36959425 wd:Q53145586
p:P2093
wds:Q34373867-CCF98FA5-45F0-47CC-9BE1-57C96175652F wds:Q34373867-CDAD59D0-2D72-491B-9E2A-D7A2FDFF08A9 wds:Q34373867-8D9C78F8-4404-4324-A614-D48896E65E62 wds:Q34373867-FEB1655A-AD7C-45F0-970E-3F185A41E564 wds:Q34373867-00DAC139-BF36-4DCD-A71A-91E13BC0C859 wds:Q34373867-02511800-7DBD-4209-A92E-7189FCF096AF wds:Q34373867-035160B9-1B74-46F3-A872-EB15DFE7E16C wds:Q34373867-C4F79F7F-48E4-4A43-8EA5-02B28CB4A4AD wds:Q34373867-182E7FBC-3123-4945-9036-9700C91958DA
wdt:P2093
Jose M Gatell Hans Jaeger Pere Domingo Steve Almond extended SPRING-2 Study Group Elena Belonosova Helmut Albrecht Sherene Min Clare Brennan
rdfs:label
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
skos:prefLabel
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
schema:name
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
p:P50
wds:Q34373867-23177C67-C72E-465E-9C9A-F3FFE81FEC2A wds:Q34373867-AA0BD9C4-9DC5-4A2E-847A-D2AB78822973 wds:Q34373867-AAE09E56-6771-4C3A-BC61-C0D7A4F03EB1
wdt:P50
wd:Q30650722 wd:Q121183517 wd:Q111669983
p:P1476
wds:Q34373867-78BCCB72-F989-49F5-A0B8-545DD89BB30E
wdt:P1476
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
p:P304
wds:Q34373867-FC032693-BFBA-45A5-8784-EE59A6E2AF7D
wdt:P304
927-935
p:P31
wds:Q34373867-4A23B487-930B-42C8-85F7-075B198B003B
wdt:P31
wd:Q13442814
p:P921
wds:Q34373867-4422B75E-DBF6-48F8-A1E0-C962C34BC990 wds:Q34373867-EF7D0BF2-6C28-4620-9DD3-F7FBDB961A78 wds:Q34373867-93CED6C4-703C-42FB-BBFF-C746C6A63A8F
wdt:P921
wd:Q50430310 wd:Q421552 wd:Q937224
p:P698
wds:Q34373867-508EEB77-11A4-4BDA-8346-D017D8B57E33
wdtn:P698
n12:24074642
wdt:P698
24074642
p:P1433
wds:Q34373867-45819AE5-07A5-4CE4-B869-80C1550113CD
wdt:P1433
wd:Q15724248
p:P433
wds:Q34373867-0D2B448C-822E-472A-946F-77D625A70928
p:P478
wds:Q34373867-EDFBC4C0-C140-47AF-84E6-876862D1C973
wdt:P433
11
wdt:P478
13
p:P356
wds:Q34373867-D651E0CC-A7DE-4E4E-80AE-92F0AF749E55
wdtn:P356
n11:S1473-3099(13)70257-3
wdt:P356
10.1016/S1473-3099(13)70257-3